Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

AbbVie stories

Nov 19, 2026

AbbVie strikes deal worth up to $2.54B with Disco Pharmaceuticals for cancer therapies

AbbVie agreed to pay up to $2.54 billion to develop antibody-drug conjugate and T cell engager cancer treatments with Disco Pharmaceuticals, a preclinical German biotech. The deal expands AbbVie's oncology pipeline targeting solid tumors.

Nov 19, 2026·2 sources
00

Top claims

  • ▪Pharmaceutical companies Bristol Myers Squibb, Pfizer, and Merck have increased their focus on bispecific antibody cancer therapies
  • ▪Disco Pharmaceuticals CEO Mark Manfredi stated that Disco Pharmaceuticals will select a development candidate in the second half of 2027
  • ▪AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Germany-based Disco Pharmaceuticals

Topics

Cancer treatmentTargeted cancer therapyDrug developmentCancer & OncologyCancer and Cancer TreatmentPharmaceutical IndustryBiotech innovation

Related entities

CologneRemagenGermanyPfizerMerck